HHS OIG Rejects Physician Royalty Plan Despite Safeguards
A new HHS OIG advisory opinion rejects a device maker's physician royalty model tied to broad product line sales, signaling that common compliance safeguards may not be enough to mitigate Anti-Kickback Statute risk.
The U.S. Department of Health and Human Services Office of Inspector General (OIG) issued an unfavorable advisory opinion rejecting an orthopedic device manufacturer’s proposed royalty model for physician consultants. The proposal would have compensated physicians with a percentage of net sales from an entire product line for broad advisory services, not just for specific products they helped invent. The OIG's rejection is notable because it came despite the manufacturer including several common compliance safeguards, such as fair-market-value compensation determined by an independent valuer and exclusions for sales tied to the consultant's own work.
The opinion signals heightened regulatory risk for life sciences companies using similar arrangements. The OIG concluded the model could violate the Anti-Kickback Statute by improperly incentivizing physicians to use their influence—through teaching and proctoring—to drive sales across the product line, blurring the line between payment for innovation and reward for marketing. The decision underscores that traditional safeguards may not be enough to protect arrangements that compensate physicians based on broad sales rather than for specific, identifiable intellectual property contributions. Companies should review existing royalty agreements to ensure a clear nexus between payment and innovation.